Wingspan Technology today announced Alliance Foundations Trials, LLC (AFT) selected Wingspan eTMF and SiteZone to create, collect, modify, and manage its clinical trial content. AFT, based in Boston and Chicago, is an academic research organization that develops and conducts cancer clinical trials, working closely with pharmaceutical partners, research collaborators and the Alliance for Clinical Trials in Oncology scientific investigators and institutional member network. AFT selected Wingspan eTMF for its easier-to-use, more transparent and more cost-effective solutions. AFT also implemented SiteZone, Wingspan’s tool for site collaboration, to create more efficient workflows and eliminate the transfer of paper documents between clinical trial sites, CRAs, and the eTMF. “AFT utilizes the Alliance network of sites for all AFT trials. We wanted a system that is easy to use for both our study teams and sites. We found that in Wingspan and Sitezone,” said Monica M. Bertagnolli, MD, President of Alliance Foundation Trials and Group Chair of the Alliance for Clinical Trials in Oncology. “Our goal is to have a single eTMF across our broad portfolio that will support both large and small studies. We believe Wingspan will deliver what we need.“ In order to facilitate a smooth and timely transition, AFT used a four-phase implementation approach. They first implemented Wingspan eTMF, then SiteZone, followed by CTMS integration, and finally migrated all content from their previous system. AFT used a risk-based approach to user acceptance testing, leveraging Wingspan’s UAT accelerator materials. This allowed additional time for user training prior to the official go-live date. About Wingspan Technology, Inc.Wingspan Technology, Inc. is the leading provider of life sciences and eClinical software solutions, including the Wingspan Life Sciences Solution platform, as well as DocWay, the SharePoint/Documentum integration product suite. Wingspan's talented and knowledgeable engineering and project management teams offer in-depth industry knowledge and experience to companies in life sciences, pharmaceutical, financial services, and other fields. About Alliance Foundation Trials, LLC Alliance Foundation Trials, LLC (AFT) seeks to fulfill the vision of the Alliance for Clinical Trials in Oncology to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. Established in 2014 as a limited liability corporation, AFT is managed by the Alliance for Clinical Trials in Oncology Foundation, which is its sole member. The AFT operational structure and funding sources are separate from the Alliance clinical trials program funded by the National Cancer Institute (NCI).
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.